About AccuraGen
AccuraGen is a Healthcare company based in Menlo Park (United States) founded in 2013. Non-invasive cancer diagnostics tests are developed using ssDNA sequencing technology. AccuraGen has raised $46.9 million across 2 funding rounds from investors including Temasek, Decheng Capital and Detong Capital. AccuraGen offers products and services including Liquid Biopsy Assay and AccuScan Whole-Genome Sequencing. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is AccuraGen, Inc. Its competitors include Guardant Health, GRAIL and Color; 3 of its 3 listed competitors have raised funding.
Company details
AccuraGen was founded in 2013 and is based in Menlo Park, United States. Operations focus on the biotechnology sector, where non-invasive diagnostics for cancer are created. Proprietary CLAmp-seq technology, based on single-strand DNA sequencing, is employed to identify circulating cell-free tumor DNA in patient samples. This approach supports early detection efforts without invasive procedures.
- Headquarters Menlo Park, United States
- SectorsHealthcare
- Website accuragen.com
- Social LinkedIn
- Legal Name Accuragen, Inc.
- Total Equity Funding$46.9M (USD)
in 2 rounds
- Latest Funding Round$40M (USD), Series B
Jun 2016
- InvestorsTemasek
& 5 more
Products & Services of AccuraGen
AccuraGen offers a comprehensive portfolio of products and services, including Liquid Biopsy Assay and AccuScan Whole-Genome Sequencing.
Detects genetic alterations in blood for cancer monitoring and therapy selection.
Analyzes cancer signals for minimal residual disease detection in patients.
Funding Insights of AccuraGen
AccuraGen has successfully raised a total of $46.9M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $40 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $46.9M
- Total Rounds 2
- Last Round Series B — $40M
- First Round $6.9M
(Jan 2015)
- Investors Count 6
All 2 funding rounds of AccuraGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $40M | Series B | – | Decheng Capital, Temasek | – |
| Jan 2015 | $6.9M | Series A | – | Decheng Capital |
6 investors in total: 6 institutional.
Investors in AccuraGen
AccuraGen has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Temasek, Decheng Capital and Detong Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science and technology sectors | decheng.com | Shanghai, China | ||
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
| dtcap.com | ||||
Startups are accelerated by Stanford-backed program in Palo Alto. | startx.com | Palo Alto, United States | ||
| yifangventures.com | ||||
Corporate backed venture capital firm investing in life sciences sector | nanfunglifesciences.com | San Francisco, United States |
Investor details for AccuraGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of AccuraGen
3 dated milestones of AccuraGen across 3 years, from founding to its latest funding, stage changes and deals.
- Founded AccuraGen is founded.
- Funding First funding round of $6.9M.
- Funding Latest funding round, Series B, of $40.0M.
Competitors of AccuraGen
AccuraGen has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Color.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| color.com | 2013 | Burlingame, United States | $491.44M | 687 | Cancer care is delivered through a virtual clinic by Color. |
Detailed competitors of AccuraGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AccuraGen
The website of AccuraGen (accuragen.com) receives about 1.2K visits a month.
- Monthly visits1.2K
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as AccuraGen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Accuragen
Complete news archive for AccuraGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AccuraGen
AccuraGen was founded in 2013 and raised its 1st funding round 2 years after it was founded.
AccuraGen is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
AccuraGen is a funded company, having raised a total of $46.9M across 2 funding rounds to date. The company's 1st funding round was a Series A of $6.9M, raised on Jan 2015.
AccuraGen was founded in 2013 and is based in Menlo Park, United States. Operations focus on the biotechnology sector, where non-invasive diagnostics for cancer are created. Proprietary CLAmp-seq technology, based on single-strand DNA sequencing, is employed to identify circulating cell-free tumor DNA in patient samples. This approach supports early detection efforts without invasive procedures.
AccuraGen's top competitors include Guardant Health, GRAIL and Color.
AccuraGen offers Liquid Biopsy Assay and AccuScan Whole-Genome Sequencing.
AccuraGen has 6 investors. Key investors include Temasek, Decheng Capital, Detong Capital, StartX, and Yifang Ventures.
AccuraGen operates through Accuragen, Inc..